: Lebrikizumab, a monoclonal antibody targeting interleukin-13, has demonstrated efficacy and safety in adults with moderate-to-severe atopic dermatitis (AD), but data in elderly patients remain limited. We conducted a retrospective multicentre study including 90 patients aged ≥60 years with moderate-to-severe AD treated with lebrikizumab across 23 Italian dermatology centres. Clinical outcomes were assessed at baseline and at weeks (W)16, W24 and W52. Mean EASI decreased from 23.24 ± 7.93 at baseline to 6.33 ± 6.54 at W16, 3.57 ± 3.74 at W24 and 2.70 ± 4.83 at W52 (p < 0.0001). EASI75 was achieved by 58.4%, 82.0% and 87.0% of patients at W16, W24 and W52, respectively. Clinical responses were similar across age groups and independent of prior biologic or JAK inhibitor exposure. Adverse events occurred in 7.8% of patients and were mainly mild. These findings support the effectiveness and safety of lebrikizumab in elderly patients with AD in real-world clinical practice.
Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study / Napolitano, M., Lauletta, G., Cimmino, M., Girolomoni, G., Pezzolo, E., Ferrucci, S.M., Narcisi, A., Borghi, A., Del Duca, E., Romanelli, M., Bonzano, L., Gori, N., Peris, K., Mandato, F., Errichetti, E., Esposito, M., Marasca, C., Rossi, M., Zerbinati, N., Galdo, G., et al.. - In: CLINICAL AND EXPERIMENTAL DERMATOLOGY. - ISSN 1365-2230. - (2026). [10.1093/ced/llag285]
Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study
Napolitano, Maddalena;Lauletta, Giuseppe;Cimmino, Marianna;Ferrucci, Silvia Mariel;Marasca, Claudio;Peduto, Tiziana;Di Sessa, Ilaria;di Vico, Francesca;Patruno, Cataldo
2026
Abstract
: Lebrikizumab, a monoclonal antibody targeting interleukin-13, has demonstrated efficacy and safety in adults with moderate-to-severe atopic dermatitis (AD), but data in elderly patients remain limited. We conducted a retrospective multicentre study including 90 patients aged ≥60 years with moderate-to-severe AD treated with lebrikizumab across 23 Italian dermatology centres. Clinical outcomes were assessed at baseline and at weeks (W)16, W24 and W52. Mean EASI decreased from 23.24 ± 7.93 at baseline to 6.33 ± 6.54 at W16, 3.57 ± 3.74 at W24 and 2.70 ± 4.83 at W52 (p < 0.0001). EASI75 was achieved by 58.4%, 82.0% and 87.0% of patients at W16, W24 and W52, respectively. Clinical responses were similar across age groups and independent of prior biologic or JAK inhibitor exposure. Adverse events occurred in 7.8% of patients and were mainly mild. These findings support the effectiveness and safety of lebrikizumab in elderly patients with AD in real-world clinical practice.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
